Consistent with this idea, pharmacological DDR1 inhibition with nilotinib, a TK inhibitor currently used in the clinic to target the BCR‐ABL oncogene in chronic myeloid leukaemia, displays a potent anti‐metastatic activity in CRC. This evidence concerns the gene DDR1 and chronic myelogenous leukemia, BCR-ABL1 positive.